Receptors 
IgD is expressed on the majority of mature B lymphocytes and is found in low quantity in serum (1). Its role in the humoral immune response is not known. We have recently shown the presence of IgD receptors (IgD-R) on T cells from mice harboring IgD-secreting plasmacytomas, TEPC-1017 or TEPC-1033, or injected with IgD produced by these plasmacytomas. Such mice exhibit significantly enhanced antibody responses of all isotypes except IgD (2, 3). The augmented ability to produce antibodies can be transferred from IgDtreated to normal mice by CD4+, Lyt 1+, CD8-T cells (4), the same subset of T cells that also exhibit IgD-R as shown by their capacity to form rosettes with IgD-coated sheep erythrocytes (IgD-SRBC); these cells bearing receptors for IgD have been called TS cells (5) . Results from these studies indicate that IgD is a cell-membrane receptor involved in T-B cell interaction (6, 7) .
Immunoglobulin isotype-specific Fc receptors (i.e., FcyR, FceR, FcuR, and FcaR) appear on cells such as macrophages, granulocytes, and lymphocytes. Some of these receptors trigger various functions, such as phagocytosis, antibody-dependent cytotoxicity, and the secretion of potent mediators (8, 9) . We previously established the isotypic specificity of IgD-R-bearing T-helper (T8) cells by showing that IgD, at concentrations -120 ,ug/ml (1.0 ,uM), competitively inhibits TS-cell rosetting, whereas IgM, IgG1, IgG2a, IgG3, IgA, or IgE fail to do so (5, 6) . Exposure of T cells to oligomeric secreted IgD (TEPC-1017 or -1033) or to antigencrosslinked monomeric secreted IgD (such as B1-8.81, a monoclonal antibody of IgD isotype) or to B-cell surface IgD crosslinked by anti-IgD or anti-immunoglobulin causes upregulation of IgD-R on these cells, both in vitro and in vivo (10) . B cells with crosslinked surface IgM do not cause such IgD-R up-regulation. Interleukin 2, interleukin 4, and interferon y also up-regulate IgD-R on CD4' polyclonal or cloned T cells (6, 11, 12) .
We sought to identify the heavy-chain domains of IgD involved in the interaction with the IgD-R on T-helper cells, and we report that IgD-R on T-helper cells are not exclusively Fc receptors but also bind equally well to the Fd domain of IgD.
MATERIALS AND METHODS
Mice and Cell Lines. Six-to eight-week-old BALB/c and CB6F1 mice were obtained from Charles River Breeding Laboratories. Two IgD-secreting plasmacytomas TEPC-1017 and -1033 (13) were maintained i.p. in pristane-primed BALB/c mice. The hybridoma B1-8.81, secreting IgD specific for the hapten 4-hydroxy-3-nitrophenyl-acetyl, was from K. Rajewsky (Institute for Genetics, University of Cologne, Cologne, F.R.G.): this hybridoma was maintained i.p. in CB6F1 mice. The T-cell hybridoma (2H10) of helper phenotype and specific for cytochrome c was maintained in Click's/ RPMI 1640 (1:1) medium; this hybridoma was provided by R. H. Schwartz (National Institute of Allergy and Infectious Diseases, Bethesda, MD).
Reagents. H8a/1 and AMS-15 are monoclonal antibodies specific for Fc8 and Fd8, respectively (14, 15) . Rabbit antimouse IgD and Fab were prepared as described (5) . Purified lectin from Griffonia simplicifolia 1 (GS-1) was donated by EY Laboratories. Purified F(ab')2 fragments of IgG were from W. 0. Weigle (Scripps Institute for Medical Research, La Jolla, CA). Recombinant interleukin 4 (rIL-4) produced by myeloma transfectants (16) subsequently isolated by affinity chromatography with the FcO-specific, HSa/1-Sepharose column. FabS fragments of naturally degraded purified IgD were also isolated by passage through this column (see Fig. 2 ). SDS/PAGE was done under reducing and nonreducing conditions.
Rosette-Forming Cefl (RFC) Assay. Splenic T cells (2.5 x 106) were incubated at 37°C for 18 hr in 1 ml of RPMI 1640 medium/2% fetal calf serum with rIL-4 (10 units-ml-1) or crosslinked IgD (100 jig/ml) overnight. These resulting TS cells were used as IgD-R bearing cells in RFC assays. T cells were examined for their expression of receptors for IgD by a rosetting method (5) . Purified IgD-, Gen.24-, KWD1-, KWD6-, or bovine serum albumin (BSA)-coated SRBC were prepared by the CrCl3-coupling method (20 blotting and by ELISA with monoclonal anti-8 antibodies (Table 1) . In contrast, Gen.24, produced by a spontaneous variant of TEPC-1017 IgD-producing cells, lacks C,83 while possessingC81 and part of the C5-hinge (23) . All mutant IgD molecules were found to bind GS-1, which was shown to bind specifically to the N-linked glycans of murine IgD (19) . We found that not only intact dimeric (TEPC-1017) and monomeric (B1-8.81, data not shown) IgD blocked IgD rosetting approximately equally, but the mutant IgD molecules examined also blocked to the same extent (Table 1) , especially when the amount for =50%o inhibition by these molecules is compared on a molar basis. Considering that TEPC-1017 is present as a dimer (260 kDa, ref. 13) , its molar effectiveness is quite comparable to that of Gen.24 (100 kDa) and KWD1 (90 kDa). In addition, all of the mutant proteins mediated rosette formation by CD4' splenic TS cells or by 2H10 CD4+, IgD-R+ T-hybridoma cells, although KWD1-coated erythrocytes gave a somewhat lower percentage of RFC than KWD6 or Gen.24 mutants (Table 1) . To confirm the data obtained with KWD6 molecules, we attempted to isolate Fc8 molecules but failed to obtain Fc8 fragments sufficiently homogeneous in size to confidently be used in inhibition studies. The heterogeneous preparation obtained, which reacted with H8a/1, did not react with rabbit anti-Fab, and had an average size of 40 kDa, inhibited IgD rosetting only 23 ± 1% at 120 ,tg/ml.
Fd and Fc Regions of IgD Compete for Binding to IgD-R.
The previous results show that KWD6 and Gen.24 mutants, in spite of their lack of C5,1 plus Cs hinge and C53 domains, respectively, each have a determinant recognized by the IgD-R. The identity of these determinants was further examined in the experiments shown in Fig. 1 by RFC crossblocking experiments. KWD6 and Gen.24 mutants were equally effective in blocking rosetting with Gen.24-coated SRBC, whereas KWD6 was quantitatively more effective than Gen.24 in blocking the rosetting with KWD6-coated SRBC, although blocking was obtained with both. These results show that the (C8,1 plus C8-hinge) and C83 domains of IgD can independently bind to the IgD-R and competitively inhibit each other for binding to the same receptor.
Common Binding Site for IgD-R Is Not Directly Determined by Amino Acid Sequence Homology. The tailpiece of the murine-secreted IgD is considerably longer (21 residues) than that of human IgD (24) . All of the mutant molecules presumably share this C-terminal amino acid sequence. To determine whether these residues played any role in the binding of these molecules to the IgD-R, we prepared FabS fragments.
We isolated FabS fragments by passing spontaneously degraded purified IgD over an Fc8-specific Ha/1-Sepharose affinity column. As shown in Fig. 2 , two IgD fragments of -66-70 kDa as well as a 90-kDa fragment were present in a stored preparation of TEPC-1017 IgD. HSa/1-Sepharose bound the 90-kDa and the 130-kDa intact IgD but not the 66-and 70-kDa fragments. Reduction of the 66-and 70-kDa fragments generated immunoglobulin light chains (25 kDa) and 32-and 36-kDa heavy-chain fragments. Immunoblotting of these unreduced IgD fragments showed that they reacted with both rabbit anti-Fab and rabbit anti-IgD (Fig. 2) , while by ELISA they reacted with AMS-15 antibody (Fd8-specific)
but not with H8a/1 (data not shown). The FabS fragments were >95% pure, as estimated by ELISA (data not shown).
As was true for the mutant proteins, FabS fragments, but not IgG Fab molecules (data not shown), bound to IgD-R, as shown by their ability to inhibit TS rosette formation with SRBC coated with intact IgD (Table 1) Another possibility to explain cross-inhibition by C,63-and C81 plus hinge-containing molecules could be through some common determinants in these regions of IgD, such as amino acid sequence homology or common carbohydrate moieties. C81 and C,63 at positions 28-40 and 24-36, respectively, show a significant degree of homology (6/13 amino acid residues) (21). These two peptides together with their neighboring residues (16-mer) were synthesized and used as inhibitors of IgD rosetting. No inhibition was seen at concentrations as high as 300 pug/ml (data not shown). rosetting seen between Gen.24 and KWD6. Moreover, these results could not readily be explained by homology in the Ct1 and C,&3 polypeptide-backbone structures. Oligopeptides, corresponding to the most homologous region of Ct,3 with C81, did not inhibit resetting. In addition, this region also shows strong homology with the murine fourth constant region of ,u heavy-chain (21), whereas IgM fails to interact with IgD-R (5). The results show, on the other hand, that the mutant molecules and the FabO share with IgD the ability to bind to GS-1, a lectin previously shown to specifically bind N-glycans isolated from IgD, while unable to bind deglycosylated IgD. This result suggests that further studies on the role of carbohydrate moieties in the binding of IgD to IgD-R are required.
The mechanism by which TS cells augment B-cell responses has not been resolved. It has been suggested that soluble IgD-binding factors, which are released by TS cells, may contribute to their immunoaugmenting properties (29) . The current IgD-R specificity data are consistent with our previously hypothesized functional role for TS cells in regulating humoral immune responses (6) . We have speculated that TS cells interact more efficiently with IgD' B cells subsequent to antigen-induced crosslinking ofmembrane IgD molecules. This speculation was from our observations that (i) both primary and secondary antibody responses are augmented by injections of IgD before the primary injection of antigen (2), and (it) B cells with crosslinked surface IgD induce up-regulation of IgD-R on T cells in vivo and in vitro (10) . Crosslinking of surface IgD with the C53-specific monoclonal antibody HO"/1 also causes such IgD-R up-regulation. Because this antibody might be expected to sterically hinder interaction ofIgD-R with the C83 portion of IgD, a role for C861 
